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ORIGINAL

ARTICLE

Identifying gaps and providing
recommendations to address
shortcomings in the investigation of
acne sequelae by the Personalising Acne:
Consensus of Experts panel
Alison Layton, MB, ChB,a,b Andrew Alexis, MD, MPH,c Hilary Baldwin, MD,d,e Stefan Beissert, MD,f
Vincenzo Bettoli, MD,g James Del Rosso, DO,h,i Brigitte Dreno, MD, PhD,j Linda Stein Gold, MD,k
Julie Harper, MD,l Charles Lynde, MD,m,n Diane Thiboutot, MD,o Jonathan Weiss, MD,p and Jerry Tan, MDq,r
York and Harrogate, United Kingdom; New York and Brooklyn, New York; New Brunswick, New Jersey;
Dresden, Germany; Ferrara, Italy; Las Vegas, Nevada; Nantes, France; Detroit, Michigan; Birmingham,
Alabama; Ontario, Canada; Hershey, Philadelphia; and Snellville, Georgia
Background: The physical sequelae of acne include erythema, hyperpigmentation, and scarring, which
are highly burdensome for patients. Early, effective treatment can potentially limit and prevent sequelae
development, but there is a need for guidance for and evidence of prevention-oriented management to
improve patient outcomes.
Objective: To identify unmet needs of acne sequelae and generate expert recommendations to address
gaps in clinical guidance.
Methods: The Personalizing Acne: Consensus of Experts panel of 13 dermatologists used a modified
Delphi approach to achieve a consensus on the clinical aspects of acne sequelae. A consensus was defined
as $75% of the dermatologists voting ‘‘agree’’ or ‘‘strongly agree.’’ All voting was electronic and blinded.
Results: The panel identified gaps in current guidance and made recommendations related to acne
sequelae. These included identification and classification of sequelae, pertinent points to consider for
patient consultations, and management aimed at reducing the development of sequelae.
Limitations: The recommendations are based on expert opinion and made in the absence of high-quality
evidence.
Conclusions: The identified gaps should help inform future research and guideline development for
acne sequelae. The consensus-based recommendations should also support the process of consultations
throughout the patient journey, helping to reduce the development and burden of acne sequelae
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through improved risk factor recognition, early discussion, and appropriate management. ( JAAD Int
2021;5:41-8.)
Key words: acne scarring; acne sequelae; acne-induced hyperpigmentation; acne-induced macular
erythema; consensus; Delphi process; postinflammatory erythema; postinflammatory hyperpigmentation.

INTRODUCTION

hyperpigmentation
is
CAPSULE SUMMARY
Acne is a prevalent, chronic
frequently long lasting and
inflammatory skin condition
may prove to be more boththat can lead to clinically releersome to the patient than
Acne sequelae are common and cause
vant sequelae, such as erythe initial acne lesions.1,12,13
substantial burden to patients. However,
thema, hyperpigmentation,
Similarly, acne-induced macevidence and guidance on prevention
and scarring.1 Acne-induced
ular erythema is frequently
and management are sparse, potentially
considered cosmetically unscarring is most commonly
compromising patient outcomes.
acceptable
and
can
atrophic but can also be hyClinical management gaps relating to
contribute to the psychosopertrophic or keloidal.2,3
acne sequelae were identified.
cial burden of acne as well as
Acne-induced macular hyperRecommendations to enhance patient
have a significant and lasting
pigmentation, also termed
outcomes were made to improve
impact on patients finan‘‘post-inflammatory hyperpigsequelae classification, risk factor
cially.1,7,16-19 The treatment
mentation,’’ describes an
identification, and patient discussion.
acquired
hypermelanosis
of acne sequelae often infrequently attributed to prior
volves costly procedural incutaneous
inflammation.4
terventions, such as laser,
radiofrequency microneedling, and chemical
Acne-induced macular erythema, also termed ‘‘postpeeling; however, high-quality evidence of the
inflammatory erythema,’’ represents persistent eryefficacy of such treatments is sparse.5,12,19,20
thema as an initial acne lesion resolves.5
There have been few formal epidemiologic
Furthermore, such interventions are often considstudies of acne sequelae; scarring is the most
ered cosmetic in nature, which limits their accessifrequently investigated. The prevalence estimates
bility to patients.21,22
for acne-induced scarring vary considerably, from
Clinical guidelines for acne have suggested that
43% to 90.8%.6,7 Although scarring risk may correlate
early and effective treatment of acne can limit
physical and psychosocial sequelae.23 However,
with increased acne severity, it also commonly
6,7
occurs with mild or moderate disease. A number
acne is a chronic disease,11 and evidence of and
of other risk factors for acne scarring have also been
guidance for the practical implementation of a longidentified, including time from acne onset and first
term, patient-centered management plan in patients
effective treatment, disease relapse, family history,
with acne are sparse.24-26 Without the best practice
intensity of immune response mounted, lesion
guidance, patients may receive suboptimal treatment
manipulation, and male sex.6,8,9 For acne-induced
and limited risk factor mitigation, potentially leading
to higher risk of acne sequelae and psychologic
hyperpigmentation, patients with darker Fitzpatrick
comorbidity.23,27
skin phototypes are more commonly affected than
10-13
those with lighter Fitzpatrick skin phototypes,
As part of a 2020 consensus project, the
Personalising Acne: Consensus of Experts (PACE)
whereas acne-induced erythema is generally considpanelists aimed to identify the unmet needs in
ered to affect, or at least be more noticeable in,
recognizing and managing acne sequelae and used
individuals with lighter Fitzpatrick skin photoan expert consensus, combined with the best availtypes.5,12 Patients frequently experience a combinaable evidence, to address gaps in clinical guidance.
tion of acne-induced sequelae.5,12
The burden of acne sequelae can be substantial.1
METHODS
Because there can be a substantial discordance
Expert panel
between a patient’s and a physician’s severity perThe expert panel consisted of 13 dermatologists
ceptions, objective assessments performed by a
from Canada (n = 2), France (n = 1), Germany (n = 1),
clinician may not be sufficient to assess individual
Italy (n = 1), the United Kingdom (n = 1), and the
burden.14 Acne-induced scars are perceived negaUnited States (n = 7). Two cochairpersons from the
tively in some societies, with affected individuals
main panel oversaw the process and were involved
seen as less attractive, confident, happy, healthy, and
in panel selection and Delphi design.
successful than those without scars.15 Acne-induced
d

d
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Abbreviation used:
PACE:

Personalising Acne: Consensus of Experts

Modified Delphi process
A modified Delphi process was used to reach a
consensus on questions pertaining to acne sequelae
identification, classification, and burden for patients
as well as pertinent points to consider for patient
consultation and management. The process consisted of a series of 5 e-surveys and an interim group
webinar between the third and fourth e-survey
(Fig 1). An initial literature search was conducted to
identify clinical management gaps in acne and the
need to make recommendations that incorporate all
presentations of acne. The search process included
an audit of acne clinical guidelines for Europe, the
United States, and Canada24-26 to identify research
gaps, followed by an additional assessment of
relevant literature to address key clinical management questions associated with the gaps identified in
the audit. The quality of evidence was rated according to the grading of recommendations assessment,
development and evaluation (GRADE) methodology28 and used to guide the e-survey content.
Further details on the process and outcomes of the
literature search can be found in the Supplemental
Information (available via Mendeley at https://data.
mendeley.com/datasets/pg8658vmz9/2.)
E-survey development and administration
Consensus statements were structured to assess
the level of agreement using the following response
range: ‘‘strongly disagree,’’ ‘‘disagree,’’ ‘‘agree,’’
‘‘strongly agree,’’ or ‘‘unable to answer.’’ A consensus
was defined as $75% of the panelists voting ‘‘agree’’
or ‘‘strongly agree.’’ Some questions were posed as
multiple-choice questions, in which several responses could be selected; the results were
presented as a consensus when chosen by $75%
of the panelists. Some questions were open ended to
allow for the development of consensus statements
in a subsequent voting round. A virtual interim
meeting was held after e-survey 3 to discuss the
direction of the subsequent surveys. The e-surveys
were programmed, administered, and the responses
collated by Ogilvy Health UK in order to maintain
blinding. The topic of acne sequelae was 1 of 4 major
topics explored in the e-surveys and virtual interim
meeting and will be the focus of this current article.
Truncal acne, longitudinal management, and patient
types were also covered and will be reported in
subsequent publications.

RESULTS
Definition of consensus recommendations
The result of the consensus statement voting is
given in brackets (12/13 voted ‘‘agree’’ or ‘‘strongly
agree’’). Some panel members occasionally voted
‘‘unable to answer.’’ These votes were not included
in the denominator. Full statements are available in
the Supplemental Information (available via
Mendeley at https://data.mendeley.com/datasets/
pg8658vmz9/2.) The elements that were considered
but not voted on are included in the ‘‘Discussion
points’’ section below.
Panelist demographics
Majority of the panelists reported that they had
consulted publications for practical advice on managing acne sequelae and found them ‘‘somewhat
helpful’’ (76.9%; 10/13). For the management of
acne-induced scarring or acne-induced hyperpigmentation, 53.9% (7/13) did not find clinical practice
guidelines useful; 38.5% (5/13) did not find them
useful for the mitigation or prevention of future acne
sequelae.
Identification and classification of acne
sequelae and their impact on patients
The gaps in and recommendations for identifying
and classifying acne sequelae and their impact on
patients are provided in Table I.
Discussion points. The panel recommended
using the terminology ‘‘acne-induced macular
erythema’’ and ‘‘acne-induced macular hyperpigmentation’’ in place of ‘‘post-inflammatory’’ to
avoid conflating morphology with pathogenesis
and to improve accuracy, since the term
‘‘macular’’ describes flat, circumscribed changes
in skin color and inflammation occurring in
patients with post-inflammatory erythema and
post-inflammatory hyperpigmentation can be
persistent as opposed to ‘‘post-inflammatory.’’
Furthermore, the prefix ‘‘acne-induced’’ provides
more specificity.
Some panelists noted that acne-induced macular
erythema might take a different hue in patients with
darker skin, eg, purple or brown.
Patients seen by the PACE panelists typically
express concerns about the permanence of acneinduced scars and other defects, such as discoloration. Resolution can be partial or complete, and
sequelae may improve but not resolve, with or
without treatment. Scarring generally has the longest
duration of acne sequelae, although active inflammation and pigment changes notably impact the
quality of life in the short term.
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Fig 1. The Personalising Acne: Consensus of Experts modified Delphi process.

Table I. Gaps in and recommendations for identifying and classifying acne sequelae and their impact on
patients, based on a consensus
Gaps
d The term ‘‘postinflammatory’’ when describing hyperpigmentation in acne is a misnomer (11/12)
d The term ‘‘postinflammatory’’ when describing erythema in acne is a misnomer (12/12)
d Scarring is the single acne sequela that has the greatest impact on patients’ quality of life (11/13)
d If present, macular hyperpigmentation (10/12) in patients with darker skin phototypes (Fitzpatrick scale IV-VI), macular
erythema (10/11), and scarring regardless of skin phototype (13/13) are some acne sequelae that have the greatest impact
on patients’ quality of life
d The following are common ([50%) concerns reported by patients specifically with regard to acne sequelae: long-term or
permanent duration (13/13); appearance (13/13); availability of options to treat them (11/13); and unmet expectations
(eg, anticipated completely ‘‘perfect’’ skin; 10/13)
Recommendations
d The prefix ‘‘acne-induced’’ should be used to describe acne sequelae to differentiate the cause from other dermatologic
conditions (13/13)
d Acne-induced scars are volumetric changes (hypertrophic or atrophic) that occur on the skin as a result of primary acne
lesions and may be permanent or may resolve over time or with treatment (12/13)
d Residual dark marks or spots that occur on the skin as a result of acne lesions are more appropriately described as
‘‘macular hyperpigmentation’’ than ‘‘postinflammatory hyperpigmentation’’ (13/13)
d Residual redness that occurs on the skin as a result of acne lesions is more appropriately described as ‘‘macular erythema’’
than ‘‘postinflammatory erythema’’ (12/12)
d Macular erythema is a common sequela of acne (11/12)
d Severe, inflammatory acne is a particular risk factor for acne-induced macular erythema (11/12)
d Acne-induced macular erythema is typically more visible in patients with lighter skin phototypes (Fitzpatrick scale I-III) (11/12)

Goals and patient consultations
The gaps in and recommendations for management goals and patient consultations concerning
acne sequelae are provided in Table II.
Discussion points. The panelists typically
discuss acne sequelae during the first consultation
and in subsequent visits. However, during the first
visit, it may be impractical or overwhelming to cover
sequelae with certain patients. Therefore, some
panelists may postpone discussion with certain
individuals, such as younger patients or those with
mild disease.

Early discussion of sequelae is important for a
number of important reasons, including to help
identify patients who are most at risk of developing
sequelae using available clinical tools,8 set treatment
expectations, provide advice for adhering to treatment (and the importance of adherence), avoid
lesion manipulation, and highlight the need to gain
control of active acne to minimize further sequelae
development and reassure patients that they have
some control in mitigating their risk of developing
scars. Although many panelists considered it important to determine the risk of acne-induced macular

JAAD INT
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Table II. Gaps in and recommendations for management goals and patient consultations concerning acne
sequelae, based on a consensus
Gap
d There is a need for better tools to support physicians in discussing the different types of acne sequelae with patients (13/13)
Recommendations
d Acne sequelae should be discussed with patients during the first consultation and revisited frequently (12/13)
d The risk of acne-induced scarring (13/13), macular erythema (10/13), and macular hyperpigmentation (12/13) should be
determined in all patients at diagnosis
d Acne-induced macular hyperpigmentation is an important consideration when managing acne patients with darker skin
phototypes (Fitzpatrick scale IV-VI) (13/13)
d Where relevant and appropriate, the family history of acne should be discussed during consultations with patients with
acne (13/13)
d Reducing the risk of acne sequelae should be included as a goal for maintenance phase (12/13)
d The following are essential elements to managing patients’ expectations regarding acne sequelae: discuss their concerns
about the effect of their disease (11/13); discuss their concerns around treatment (10/13); discuss their expectations of
treatment (11/13); highlight that improvement may only be observed in the long term (10/13); be realistic with them
about outcomes (11/13); emphasize the need for control of active acne to reduce the risk of developing sequelae (13/13);
emphasize the role of modifiable risk factors (eg, lesion excoriation, adherence to medication) in reducing the risk of
developing sequelae (13/13); and discuss management options for sequelae (10/13)
d Visual aids (12/13) and digital aids (11/11) would be valuable tools to support discussions of different acne sequelae with
patients
d The following educational materials or tools would be most useful to support discussions of acne sequelae with patients:
standardized definitions of sequelae (10/13); photographs (10/13); and apps (10/13)

erythema and hyperpigmentation in their patients at
the time of diagnosis, scarring risk was considered
the highest priority to discuss because scars are least
likely to resolve over time without treatment.

Table III. Gaps in and recommendations for the
treatment and management of acne sequelae,
based on a consensus

Treatment and management
The gaps in and recommendations for the treatment and management of acne sequelae are provided in Table III.
Discussion points. Typically, panelists use
early aggressive therapy with combination regimes
targeting acne pathophysiology and adopt topical
retinoids as part of the regimes to prevent acne
scarring, moving to oral retinoids if the patient does
not respond. The panelists did not vote for any
statements relating to specific treatments for acne
sequelae.

Gaps
d There is a need for high-quality evidence for effective
interventions to prevent (13/13) and manage existing
(13/13) acne-induced scarring
d There is a need for high-quality evidence for effective
interventions to prevent (12/12) and manage existing
(12/13) acne-induced macular hyperpigmentation
d There is a need for high-quality evidence for effective
interventions to prevent (11/12) and manage existing
(10/11) acne-induced macular erythema
Recommendations
d Early intervention with effective treatments is an optimal
approach for preventing acne sequelae (13/13)
d A patient should be referred to a dermatologist when
there is evidence of scarring (12/13)

General discussion
The sequelae of acne are common and can be
long lasting and burdensome for patients. Here, the
PACE panel identified gaps relating to acne sequelae
recognition, classification, and discussion with patients and generated recommendations to improve
patient care.
The key PACE recommendations are: those helping physicians identify patients with acne-induced
scarring and scarring risk factors, eg, the presence of
family history, and promoting the discussion of acne
sequelae risk with patients early in the treatment

journey. The discussion of sequelae with patients
with acne can also help address patient-related
factors that contribute to sequelae development,
such as lesion manipulation and treatment nonadherence. The potential for acne sequelae requires
greater forethought in patients with darker
Fitzpatrick skin phototypes, which should form a
part of their patient-centered management plan.29
The PACE panel recommended practical strategies to
facilitate these discussions with patients and set
realistic expectations for acne sequelae. In patients
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with existing or newly developed acne-induced
scarring, the self-assessment of clinical acne-related
scars and facial acne scar quality of life patientoriented tools can help clinicians assess the severity
and impact of acne scars30; however, tools for
assessing other acne-induced sequelae are currently
lacking.
Risk factors for acne sequelae have been
identified6,8,13,29,31,32; the mitigation of their development depends on identifying patients who are
most at risk as well as early and effective treatment of
active acne. A risk assessment tool for acne scarring
is under development by another group, which
could help alert patients to the risk of scar development and has the potential to be a valuable public
health measure, given the considerable associated
morbidity.33
Acne-induced hyperpigmentation and acneinduced macular erythema have been identified as
transitional lesions for atrophic scars.31 Although the
pathogenesis of acne sequelae is complex, ongoing
inflammation appears to be a key underlying cause
of atrophic scar development.9 Indeed, even prior to
acne lesion formation and in the absence of
Cutibacterium acnes, inflammatory processes can
be detected, and they persist through to scar formation.34 Similarly, multiple identified risk factors for
acne-induced scarring, including longer duration to
initiate effective treatment and disease relapse,6
indicate ongoing inflammation. Therefore, the
PACE panel recommended that early treatment of
active acne can help optimize patient outcomes,
which is in line with the proposed pathophysiology
of acne-induced sequelae development. Elsewhere,
it has been proposed that treatment with topical
agents, such as retinoids, benzoyl peroxide, and
certain antibiotics, should form a part of the first-line
treatment strategy to optimize outcomes for patients
with acne.35 Now, there is evidence to suggest that
retinoids play a role in acne atrophic scar repair in
the absence of primary acne lesions36 and that fixeddose combination, such as adapalene and benzoyl
peroxide, have synergistic effects on acne lesions
and the mitigation of acne scars.35
A strength of this project is the inclusion of experts
from various countries who treat a range of patients
across a spectrum of presentations in daily practice.
Recommendations based on consolidated expertise
using the egalitarian Delphi method can be considered an appropriate interim measure to support
clinical management when high-quality evidence is
either not available or not practical.37-39 However,
some concerns have been expressed over bias and
reproducibility in the Delphi process, stating that it is
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not necessarily an ‘‘evidence-based’’ process
because it relies on clinical opinion.40,41 A potential
limitation is that the panel did not fully represent a
global perspective of acne (the experts being from
Europe and North America); therefore, the recommendations and conclusions made may not be
applicable on a global basis. A number of panelists
frequently treat patients across the spectrum,
including those with darker Fitzpatrick skin phototypes, which led to recommendations for recognizing and managing acne sequelae in patients with
darker Fitzpatrick skin phototypes and is itself a
major strength of the PACE recommendations.
However, perspectives from experts practicing in
regions beyond North America and Europe would
have added valuable insights, not only for recognizing and managing acne sequelae in patients with
other Fitzpatrick skin phototypes but also for clinical,
cultural, and systemic health care system practices
that can influence acne management. In addition,
these recommendations did not include the patients’
perspective, which can also add a valuable insight
when incorporated.
The present panel also recommended several
areas for further work specific to acne sequelae.
Although recommendations for treatment options to
prevent and manage acne sequelae are available in
the literature,42,43 additional high-quality evidence is
needed to support evidence-based clinical management guidelines. The recommendations herein
could additionally be used to inform the development of future treatment algorithms for acne
sequelae. Visual and digital aids were suggested as
useful tools to support discussions of acne sequelae
with patients. However, it is important to consider
whether such tools may induce stress and anxiety in
certain individuals, which might be mitigated
through use of cartoonized versions. Furthermore,
there may be a benefit in terms of aids that can be
provided directly to patients, thus relieving some of
the burden on the physician. The distribution of the
updated sequelae lexicon can help standardize
terminology among physicians and support conversations with patients by enhancing their understanding of sequelae. Acronyms of the new terminologies
may be useful in clinical practice. Such acronyms
should be intuitive and differentiated from existing
medical acronyms (eg, AISc [acne-induced scarring],
AIMacPig [acne-induced macular pigmentation], and
AIMacEry [acne-induced macular erythema]). Of
note, an individual care pathway is currently under
development by the PACE panel, which will include
acne sequelae as a consideration for holistic patient
management throughout the treatment journey.
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CONCLUSIONS
The PACE panel identified gaps that can help
guide further work and research in the field of acne
sequelae identification, prevention, and management. These recommendations can support local
guideline development and patient consultations,
thus helping to relieve the burden of acne sequelae
in patients through improved risk factor recognition,
early discussion, and prevention at all stages of the
patient’s journey.
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